Aclarion, Inc. (NASDAQ: ACON) experienced a significant surge in its stock value on the US market during the recent weekend session, witnessing a remarkable 52.28% increase to reach a closing price of $2.84. This upward movement can be attributed to a strategic expansion initiative undertaken by the company.
Aclarion (ACON) recently announced the availability of Nociscan in the greater Phoenix, AZ market, specifically at the Barrow Neurological Institute, where Dr. Juan Uribe and other esteemed physicians are addressing chronic low back pain cases. Dr. Uribe, a leading neurosurgeon, advocates for a comprehensive approach to spine treatment, with a focus on applying minimally invasive spine surgery to complex degenerative diseases.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
His dedication to alleviating pain associated with spinal disorders is evident in his career, where he has consistently advanced treatment methodologies. One of the leading authorities on neurosurgery connected to Barrow Neurological Institute, Dr. Uribe, has pioneered new approaches to the management of persistent low back pain. His dedication to defying convention and appreciating creativity, together with his focus on research and instruction, has made a substantial impact on the subject.
Chronic low back pain (cLBP) stands as a major contributor to opioid addiction in the U.S. and is identified as the most costly diagnosis in the country. Aclarion’s innovative Nociscan solution, operating as the first evidence-supported Software as a Service (SaaS) platform, offers a noninvasive method for physicians to distinguish between painful and nonpainful discs in the lumbar spine.
By objectively quantifying chemical biomarkers associated with disc pain and utilizing proprietary algorithms, Nociscan aids in identifying potential sources of pain in the lumbar spine. It gives vital information about the exact site of a patient’s low back discomfort when paired with other diagnostic equipment, allowing medical professionals to tailor treatment plans.
A notable milestone for Aclarion is the recent announcement of the completion of the 1,000th commercial Nociscan exam. The company also highlighted the increased accessibility of MRIs by key opinion leaders (KOLs) as a pivotal factor supporting the anticipated growth in scan volume throughout 2024. The activation of the Phoenix market marks the first significant catalyst for the company in the current year.
